The DOI matches its Crossref record; 43 of the 44 references it cites were found in a registry or an index.
Fibrillar amyloid-β burden in cognitively normal people at 3 levels of genetic risk for Alzheimer's disease
Open accessAbstract
Fibrillar amyloid-beta (Aβ) is found in the brains of many cognitively normal older people. Whether or not this reflects a predisposition to Alzheimer's disease (AD) is unknown. We used Pittsburgh Compound B (PiB) PET to characterize the relationship between fibrillar Aβ burden and this predisposition in cognitively normal older people at 3 mean levels of genetic risk for AD. Dynamic PiB PET scans, the Logan method, statistical parametric mapping, and automatically labeled regions of interest (ROIs) were used to characterize and compare cerebral-to-cerebellar PIB distribution volume ratios, reflecting fibrillar Aβ burden, in 28 cognitively normal persons (mean age, 64 years) with a reported family history of AD and 2 copies, 1 copy, and no copies of the apolipoprotein E (APOE) ε4 allele. The 8 ε4 homozygotes, 8 heterozygotes, and 12 noncarriers did not differ significantly in terms of age, sex, or cognitive scores. Fibrillar Aβ was significantly associated with APOE ε4 carrier status and ε4 gene dose in AD-affected mean cortical, frontal, temporal, posterior cingulate-precuneus, parietal, and basal ganglia ROIs, and was highest in an additional homozygote who had recently developed mild cognitive impairment. These findings suggest that fibrillar Aβ burden in cognitively normal older people is associated with APOE ε4 gene dose, the major genetic risk factor for AD. Additional studies are needed to track fibrillar Aβ accumulation in persons with different kinds and levels of AD risk; to determine the extent to which fibrillar Aβ, alone or in combination with other biomarkers and risk factors, predicts rates of cognitive decline and conversion to clinical AD; and to establish the role of fibrillar Aβ imaging in primary prevention trials.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Crossing a transgenic mouse model of AD that has high levels of human Aβ in the brain with human APOE targeted replacement mice demonstrated age-dependent and APOE isoform-dependent (E4>>E3>E2) Aβ deposition and amyloid burden in the brain in a manner that recapitulates the human condition observed in pre-symptomatic elderly APOE4 carriers as well as AD patients.18–21”
From AAVrh.10-Mediated APOE2 Central Nervous System Gene Therapy for APOE4-Associated Alzheimer's Disease (2018) · cites this paper as [20]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“the amyloid deposition spreads, and the disease pathogenesis progressively involves a broad region of the brain”
From AAVrh.10-Mediated APOE2 Central Nervous System Gene Therapy for APOE4-Associated Alzheimer's Disease (2018) · cites this paper as [20]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The association of the APOE4 isoform with amyloid deposition has been well established in human studies, where APOE4 carriers exhibit higher A β plaque burden and earlier onset of amyloid positivity compared with non-carriers 35 -37 .”
From APOE2 attenuates APOE4-associated amyloid pathology and related toxicity in a mouse model of Alzheimer’s disease (2026) · cites this paper as [37]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“APOE status has been found to modulate the onset of extracellular amyloid plaque deposition, one of the key pathognomonic features of the disease (6, 7).”
From Human ApoE isoforms differentially regulate brain amyloid-β peptide clearance (2011) · cites this paper as [6]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Additionally, the APOE ε4 allele increases brain amyloid burden assessed by PIB-PET imaging in a gene dose-dependent manner (6).”
From Human ApoE isoforms differentially regulate brain amyloid-β peptide clearance (2011) · cites this paper as [6]
Experimental — accuracy not yet measured
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“APOE isoform-dependent amyloid deposition has been consistently observed in humans and Aβ depositing mouse models (Holtzman et al., 2000; Bales et al., 2009; Reiman et al., 2009; Morris et al., 2010).”
From Haploinsufficiency of Human APOE Reduces Amyloid Deposition in a Mouse Model of Amyloid-β Amyloidosis (2011) · cites this paper as Reiman et al., 2009
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The ε4 allele increased brain amyloid burden in a dose-dependent manner in normal elderly individuals and in mild cognitive impairment patients [93,94].”
From Plasma levels of apolipoprotein E, APOE genotype and risk of dementia and ischemic heart disease: A review (2016) · cites this paper as [93]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“This finding has now been confirmed more directly in a study that showed cognitively normal subjects had an ε4 dose-dependent increase in fibrillar Aβ burden in brain as detected with an amyloid imaging agent (Reiman et al., 2009).”
From The role of apolipoprotein E in Alzheimer's disease (2009) · cites this paper as Reiman et al., 2009
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“This possibility has remained unaddressed, because case–control studies without neuropathological or biomarker assessments of AD may have underestimated the impact of APOE genotypes on Alzheimer’s dementia ORs due to the confounding effects of APOE genotypes on the percentages of neuropathologically misclassified cases and controls8–10.”
From Exceptionally low likelihood of Alzheimer’s dementia in APOE2 homozygotes from a 5,000-person neuropathological study (2020) · cites this paper as [9]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Due to the prioritized ascertainment of those cases who met the clinical and neuropathological criteria for Alzheimer’s dementia and those unimpaired controls without AD, the number of misclassified cases and controls available through the AD Genetics Consortium12 is much smaller than our estimated number of neuropathologically misclassified cases and controls8–11, limiting our ability to clarify”
From Exceptionally low likelihood of Alzheimer’s dementia in APOE2 homozygotes from a 5,000-person neuropathological study (2020) · cites this paper as [9]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“In a previous autopsy study, we found that 25% of persons with the clinical diagnosis of mild-to-moderate Alzheimer’s dementia lacked at least moderately frequent neuritic plaques, one of the cardinal features of AD, including 37% of APOE4 non-carriers and 13% of carriers, findings that are consistent with those in living patients9,10.”
From Exceptionally low likelihood of Alzheimer’s dementia in APOE2 homozygotes from a 5,000-person neuropathological study (2020) · cites this paper as [9]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Folstein, M. F., Folstein, S. E., & McHugh, P. R. (1975) · Journal of Psychiatric Research · doi:10.1016/0022-3956(75)90026-6 · Cited by 88,282
Tzourio-Mazoyer, N., Landeau, B., Papathanassiou, D., Crivello, F., Etard, O., Delcroix, N., Mazoyer, B., & Joliot, M. (2002) · NeuroImage · doi:10.1006/nimg.2001.0978 · Cited by 16,319
The Amyloid Hypothesis of Alzheimer’s Disease: Progress and Problems on the Road to Therapeutics
Hardy, J., & Selkoe, D. J. (2002) · Science · doi:10.1126/science.1072994 · Cited by 13,864
Co-Planar Stereotaxic Atlas of the Human Brain
Talairach, J., & Tournoux, P. (1988) · Medical Entomology and Zoology · Cited by 11,798
Corder, E. H., Saunders, A. M., Strittmatter, W. J., Schmechel, D. E., Gaskell, P. C., Small, G. W., Roses, A. D., Haines, J. L., & Pericak-Vance, M. A. (1993) · Science · doi:10.1126/science.8346443 · Cited by 9,429
Co-planar stereotaxic atlas of the human brain
Laitinen, L. (1989) · Clinical Neurology and Neurosurgery · doi:10.1016/0303-8467(89)90128-5 · Cited by 7,565
Winblad, B., Palmer, K., Kivipelto, M., Jelic, V., Fratiglioni, L., Wahlund, L. ‐., Nordberg, A., Bäckman, L., Albert, M., Almkvist, O., et al. (2004) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2004.01380.x · Cited by 4,946
Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound‐B
Klunk, W. E., Engler, H., Nordberg, A., Wang, Y., Blomqvist, G., Holt, D. P., Bergström, M., Savitcheva, I., Huang, G., Estrada, S., et al. (2004) · Annals of Neurology · doi:10.1002/ana.20009 · Cited by 4,496
Self-citationStrittmatter, W. J., Saunders, A. M., Schmechel, D., Pericak-Vance, M., Enghild, J., Salvesen, G. S., & Roses, A. D. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.5.1977 · Cited by 4,268 · cited 1×
“The APOE 4 allele is associated with increased cerebral and vascular A deposition in AD (25), and the ApoE E4 isoform is associated with increased A binding, fibrillization, and cerebral and vascular A deposition (13, 26), as well as with decreased ApoE-mediated A clearance and degradation (27–29).”
BackgroundRestriction isotyping of human apolipoprotein E by gene amplification and cleavage with HhaI.
Hixson, J., & Vernier, D. (1990) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)43176-1 · Cited by 2,933
Flagged first, then by citations
1 of the 44 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
Items 201–300 of 787
Donix, M., Burggren, A. C., Suthana, N., Siddarth, P., Ekstrom, A. D., Krupa, A. K., Jones, M., Rao, A., Martin‐Harris, L., Ercoli, L. M., et al. (2010) · NeuroImage · doi:10.1016/j.neuroimage.2010.06.009 · Cited by 96
Genetics of Alzheimer’s Disease
Ridge, P. G., Ebbert, M., & Kauwe, J. S. K. (2013) · BioMed Research International · doi:10.1155/2013/254954 · Cited by 104
Potter, P. E., Rauschkolb, P. K., Pandya, Y., Sue, L. I., Sabbagh, M. N., Walker, D. G., & Beach, T. G. (2011) · Acta Neuropathologica · doi:10.1007/s00401-011-0831-1 · Cited by 94
Richter‐Schmidinger, T., Alexopoulos, P., Horn, M., Maus, S., Reichel, M., Rhein, C., Lewczuk, P., Sidiropoulos, C., Kneib, T., Perneczky, R., et al. (2010) · Journal of Neural Transmission · doi:10.1007/s00702-010-0539-8 · Cited by 97
The Role of Neurovascular System in Neurodegenerative Diseases
Ahmad, A., Patel, V., Xiao, J., & Khan, M. M. (2020) · Molecular Neurobiology · doi:10.1007/s12035-020-02023-z · Cited by 97
Litvinchuk, A., Huynh, T. V., Shi, Y., Jackson, R. J., Finn, M. B., Manis, M., Francis, C. M., Tran, A. C., Sullivan, P. M., Ulrich, J. D., et al. (2021) · Annals of Neurology · doi:10.1002/ana.26043 · Cited by 91
Absolute 10-year risk of dementia by age, sex and APOE genotype: a population-based cohort study
Rasmussen, K. L., Tybjærg-Hansen, A., Nordestgaard, B. G., & Frikke-Schmidt, R. (2018) · Canadian Medical Association Journal · doi:10.1503/cmaj.180066 · Cited by 91
Shi, J., Thompson, P. M., Gutman, B. A., & Wang, Y. (2013) · NeuroImage · doi:10.1016/j.neuroimage.2013.04.018 · Cited by 92
A coding variant in CR1 interacts with APOE-ɛ4 to influence cognitive decline
Keenan, B. T., Shulman, J. M., Chibnik, L. B., Raj, T., Tran, D., Sabuncu, M. R., Initiative, T. A. D. N., Allen, A. N., Corneveaux, J. J., Hardy, J., et al. (2012) · Human Molecular Genetics · doi:10.1093/hmg/dds054 · Cited by 97
Self-citationIndividual estimates of age at detectable amyloid onset for risk factor assessment
Bilgel, M., An, Y., Zhou, Y., Wong, D. F., Prince, J. L., Ferrucci, L., & Resnick, S. M. (2015) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2015.08.166 · Cited by 94
Effect of Complement CR1 on Brain Amyloid Burden During Aging and Its Modification by APOE Genotype
Thambisetty, M., An, Y., Nalls, M., Sojkova, J., Swaminathan, S., Zhou, Y., Singleton, A. B., Wong, D. F., Ferrucci, L., Saykin, A. J., et al. (2013) · Biological Psychiatry · doi:10.1016/j.biopsych.2012.08.015 · Cited by 90
Targeting Aβ and tau in Alzheimer's disease, an early interim report
Golde, T. E., Petrucelli, L., & Lewis, J. (2010) · Experimental Neurology · doi:10.1016/j.expneurol.2009.07.035 · Cited by 89
Molecular imaging in dementia: Past, present, and future
Laforce, R. J., Soucy, J., Sellami, L., Dallaire‐Théroux, C., Brunet, F., Bergeron, D., Miller, B. L., & Ossenkoppele, R. (2018) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2018.06.2855 · Cited by 88
Serum albumin and beta-amyloid deposition in the human brain
Kim, J. W., Byun, M. S., Lee, J. H., Yi, D., Jeon, S. Y., Sohn, B. K., Lee, J.-Y., Shin, S. A., Kim, Y. K., Kang, K. M., et al. (2020) · Neurology · doi:10.1212/wnl.0000000000010005 · Cited by 87
Mosconi, L., Murray, J., Davies, M., Williams, S., Pirraglia, E., Spector, N. C., Tsui, W. H., Li, Y., Butler, T., Osorio, R. S., et al. (2014) · BMJ Open · doi:10.1136/bmjopen-2014-004850 · Cited by 89
Coffee intake and decreased amyloid pathology in human brain
Kim, J. W., Byun, M. S., Yi, D., Lee, J. H., Jeon, S. Y., Jung, G., Lee, H. N., Sohn, B. K., Lee, J.-Y., Kim, Y. K., et al. (2019) · Translational Psychiatry · doi:10.1038/s41398-019-0604-5 · Cited by 86
Laws, S. M., Gaskin, S., Woodfield, A., Srikanth, V. K., Bruce, D. G., Fraser, P. E., Porter, T., Newsholme, P., Wijesekara, N., Burnham, S. C., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-09577-4 · Cited by 98
Apolipoprotein E ε4 modulates functional brain connectome in A lzheimer's disease
Wang, J., Wang, X., He, Y., Yu, X., Wang, H., & He, Y. (2015) · Human Brain Mapping · doi:10.1002/hbm.22740 · Cited by 87
Brody, A. H., & Strittmatter, S. M. (2017) · Advances in pharmacology · doi:10.1016/bs.apha.2017.09.007 · Cited by 89
Quantitative imaging of protein targets in the human brain with PET
Gunn, R. N., Slifstein, M., Searle, G. E., & Price, J. C. (2015) · Physics in Medicine and Biology · doi:10.1088/0031-9155/60/22/r363 · Cited by 86
Self-citationDynamic changes of CSF sTREM2 in preclinical Alzheimer’s disease: the CABLE study
Ma, L., Tan, L., Bi, Y., Shen, X., Xu, W., Ma, Y., Li, H., Dong, Q., & Yu, J. (2020) · Molecular Neurodegeneration · doi:10.1186/s13024-020-00374-8 · Cited by 89
Soldan, A., Pettigrew, C. A., Li, S., Wang, M., Moghekar, A., Selnes, O. A., Albert, M., & O’Brien, R. (2013) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2013.06.017 · Cited by 89
Imaging Brain Effects of APOE4 in Cognitively Normal Individuals Across the Lifespan
Fouquet, M., Besson, F. L., Gonneaud, J., Joie, R. L., & Chételat, G. (2014) · Neuropsychology Review · doi:10.1007/s11065-014-9263-8 · Cited by 89
Apolipoprotein E gene polymorphism and Alzheimer's disease in Chinese population: a meta-analysis
Liu, M., Bian, C., Zhang, J., & Wen, F. (2014) · Scientific Reports · doi:10.1038/srep04383 · Cited by 72
Gray matter network associated with risk for Alzheimer's disease in young to middle-aged adults
Alexander, G. E., Bergfield, K. L., Chen, K., Reiman, E. M., Hanson, K. D., Lin, L., Bandy, D. J., Caselli, R. J., & Moeller, J. R. (2012) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2012.01.014 · Cited by 91
Self-citationAmyloid load in nondemented brains correlates with APOE e4
Caselli, R. J., Walker, D. G., Sue, L. I., Sabbagh, M. N., & Beach, T. G. (2010) · Neuroscience Letters · doi:10.1016/j.neulet.2010.02.016 · Cited by 85
Self-citationJohnstone, D. M., Milward, E. A., Berretta, R. E., Moscato, P., & Initiative, A. D. N. (2012) · PLoS ONE · doi:10.1371/journal.pone.0034341 · Cited by 83
The Complex Role of Apolipoprotein E in Alzheimer’s Disease: an Overview and Update
Mahoney‐Sanchez, L., Belaidi, A. A., Bush, A. I., & Ayton, S. (2016) · Journal of Molecular Neuroscience · doi:10.1007/s12031-016-0839-z · Cited by 84
Caselli, R. J., Beach, T. G., Knopman, D. S., & Graff-Radford, N. R. (2017) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2017.02.011 · Cited by 81
Self-citationMurine models of Alzheimer's disease and their use in developing immunotherapies
Wısnıewskı, T., & Sigurdsson, E. M. (2010) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2010.05.004 · Cited by 84
Mosconi, L., Walters, M., Sterling, J. L., Quinn, C. G., McHugh, P. F., Andrews, R. D., Matthews, D. C., Ganzer, C. A., Osorio, R. S., Isaacson, R., et al. (2018) · BMJ Open · doi:10.1136/bmjopen-2017-019362 · Cited by 86
Aβ and cognitive change: Examining the preclinical and prodromal stages of Alzheimer's disease
Lim, Y. Y., Maruff, P. T., Pietrzak, R. H., Ellis, K. A., Darby, D., Ames, D. J., Harrington, K., Martins, R. N., Masters, C. L., Szoeke, C. E. I., et al. (2014) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2013.11.005 · Cited by 84
Association of hypometabolism and amyloid levels in aging, normal subjects
Lowe, V. J., Weigand, S. D., Senjem, M. L., Vemuri, P., Jordan, L. G., Kantarci, K., Boeve, B. F., Jack, C. R., Knopman, D. S., & Petersen, R. C. (2014) · Neurology · doi:10.1212/wnl.0000000000000467 · Cited by 83
Lipid Metabolism and Glial Lipoproteins in the Central Nervous System
Hayashi, H. (2011) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.34.453 · Cited by 80
11C-PiB Imaging of Human Immunodeficiency Virus–Associated Neurocognitive Disorder
Ances, B. M. (2012) · Archives of Neurology · doi:10.1001/archneurol.2011.761 · Cited by 78
Staging Alzheimer's disease progression with multimodality neuroimaging
Ewers, M., Frisoni, G. B., Teipel, S. J., Grinberg, L. T., Amaro, E., Heinsen, H., Thompson, P. M., & Hampel, H. J. (2011) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2011.06.004 · Cited by 81
Midlife predictors of Alzheimer's disease
Bendlin, B. B., Carlsson, C. M., Gleason, C. E., Johnson, S. C., Sodhi, A., Gallagher, C. L., Puglielli, L., Engelman, C. D., Ries, M. L., Xu, G., et al. (2009) · Maturitas · doi:10.1016/j.maturitas.2009.12.014 · Cited by 81
Lista, S., Garaci, F., Ewers, M., Teipel, S. J., Zetterberg, H., Blennow, K., & Hampel, H. J. (2013) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2013.04.506 · Cited by 78
Reitz, C. (2012) · Journal of Alzheimer s Disease · doi:10.3233/jad-2011-110599 · Cited by 76
Choe, Y. M., Sohn, B. K., Choi, H. J., Byun, M. S., Seo, E. H., Han, J., Kim, Y. K., Yoon, E. J., Lee, J. M., Park, J., et al. (2014) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2014.01.013 · Cited by 75
Role of HIV in Amyloid Metabolism
Ortega, M., & Ances, B. M. (2014) · Journal of Neuroimmune Pharmacology · doi:10.1007/s11481-014-9546-0 · Cited by 78
Cholesterol-related genes in Alzheimer's disease
Wollmer, M. A. (2010) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2010.05.009 · Cited by 78
Chiotis, K., Saint‐Aubert, L., Boccardi, M., Gietl, A. F., Picco, A., Varrone, A., Garibotto, V., Herholz, K., Nobili, F. M., Nordberg, A. K., et al. (2017) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2016.07.012 · Cited by 75
Beach, T. G., Sue, L. I., Walker, D. G., Sabbagh, M. N., Serrano, G., Dugger, B. N., Mariner, M., Yantos, K., Henry-Watson, J., Chiarolanza, G., et al. (2012) · Journal of Alzheimer s Disease · doi:10.3233/jad-2011-111340 · Cited by 74
Chen, Y. J., Rosario, B. L., Mowrey, W. B., Laymon, C. M., Lu, X., López, O. L., Klunk, W. E., Lopresti, B. J., Mathis, C. A., & Price, J. C. (2015) · Journal of Nuclear Medicine · doi:10.2967/jnumed.114.152405 · Cited by 77
Self-citationUnderstanding the cause of sporadic Alzheimer’s disease
Zetterberg, H., & Mattsson, N. (2014) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.2014.915740 · Cited by 73
Ramanan, V. K., Castillo, A. M., Knopman, D. S., Graff‐Radford, J., Lowe, V. J., Petersen, R. C., Jack, C. R., Mielke, M. M., & Vemuri, P. (2019) · JAMA Network Open · doi:10.1001/jamanetworkopen.2019.13909 · Cited by 74
Proteome-Based Plasma Markers of Brain Amyloid-β Deposition in Non-Demented Older Individuals
Thambisetty, M., Tripaldi, R., Riddoch‐Contreras, J., Hye, A., An, Y., Campbell, J., Sojkova, J., Kinsey, A. M., Lynham, S., Zhou, Y., et al. (2011) · Journal of Alzheimer s Disease · doi:10.3233/jad-2010-101350 · Cited by 72
Intravenous Delivery of Targeted Liposomes to Amyloid-β Pathology in APP/PSEN1 Transgenic Mice
Tanifum, E. A., Dasgupta, I., Srivastava, M., Bhavane, R. C., Sun, L., Berridge, J., Pourgarzham, H., Kamath, R., Espinosa, G., Cook, S. C., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0048515 · Cited by 72
Shi, J., Leporé, N., Gutman, B. A., Thompson, P. M., Baxter, L. C., Caselli, R. J., Wang, Y., & Initiative, A. D. N. (2014) · Human Brain Mapping · doi:10.1002/hbm.22447 · Cited by 74
Self-citationThe neuropsychology of normal aging and preclinical Alzheimer's disease
Caselli, R. J., Locke, D. E. C., Dueck, A. C., Knopman, D. S., Woodruff, B. K., Hoffman‐Snyder, C., Rademakers, R., Fleisher, A., & Reiman, E. M. (2013) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2013.01.004 · Cited by 73
Self-citationRayaprolu, S., Gao, T., Xiao, H., Ramesha, S., Weinstock, L. D., Shah, J., Duong, D. M., Dammer, E. B., Webster, J. A., Lah, J. J., et al. (2019) · doi:10.1101/802694 · Cited by 71
Whitehair, D. C., Sherzai, A., Emond, J. A., Raman, R., Aisen, P. S. S., Petersen, R. C., Fleisher, A., & Study, A. D. C. (2010) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2009.12.003 · Cited by 73
CSF Apo-E levels associate with cognitive decline and MRI changes
Initiative, F. T. A. D. N., Toledo, J. B., Da, X., Weiner, M. W., Wolk, D. A., Xie, S. X., Arnold, S. E., Davatzikos, C., Shaw, L. M., & Trojanowski, J. Q. (2014) · Acta Neuropathologica · doi:10.1007/s00401-013-1236-0 · Cited by 71
Shinohara, M., Petersen, R. C., Dickson, D. W., & Bu, G. (2013) · Acta Neuropathologica · doi:10.1007/s00401-013-1086-9 · Cited by 56
Family History and APOE-4 Genetic Risk in Alzheimer’s Disease
Donix, M., Small, G. W., & Bookheimer, S. Y. (2012) · Neuropsychology Review · doi:10.1007/s11065-012-9193-2 · Cited by 78
Reiman, E. M., Chen, K., Langbaum, J. B. S., Lee, W., Reschke, C., Bandy, D. J., Alexander, G. E., & Caselli, R. J. (2009) · NeuroImage · doi:10.1016/j.neuroimage.2009.07.025 · Cited by 73
Self-citationPathophysiology of Alzheimer’s Disease
Yarns, B. C., Holiday, K. A., Carlson, D. M., Cosgrove, C. K., & Melrose, R. J. (2022) · Psychiatric Clinics of North America · doi:10.1016/j.psc.2022.07.003 · Cited by 68
Mosconi, L., Rinne, J. O., Tsui, W. H., Murray, J., Li, Y., Glodzik, L., McHugh, P. F., Williams, S., Cummings, M., Pirraglia, E., et al. (2012) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2012.03.002 · Cited by 69
Mukhopadhyay, S., & Banerjee, D. (2021) · Journal of Alzheimer s Disease · doi:10.3233/jad-215065 · Cited by 66
PET imaging of mGluR5 in Alzheimer’s disease
Mecca, A. P., McDonald, J. W., Michalak, H. R., Godek, T. A., Harris, J. E., Pugh, E., Kemp, E. C., Chen, M.-K., Salardini, A., Nabulsi, N., et al. (2020) · Alzheimer s Research & Therapy · doi:10.1186/s13195-020-0582-0 · Cited by 66
Investigating Gains in Neurocognition in an Intervention Trial of Exercise (IGNITE): Protocol
Erickson, K. I., Grove, G., Burns, J. M., Hillman, C. H., Kramer, A. F., McAuley, E., Vidoni, E. D., Becker, J. T., Butters, M. A., Gray, K., et al. (2019) · Contemporary Clinical Trials · doi:10.1016/j.cct.2019.105832 · Cited by 72
Self-citationThe efficacy of plasma biomarkers in early diagnosis of Alzheimer's disease
Wang, T., Xiao, S., Liu, Y., Lin, Z., Su, N., Li, X., Li, G., Zhang, M., & Fang, Y. (2013) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.4053 · Cited by 67
Distinct pattern of hypometabolism and atrophy in preclinical and predementia Alzheimer's disease
Kljajević, V., Grothe, M. J., Ewers, M., & Teipel, S. J. (2014) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2014.04.006 · Cited by 67
Changes in Aβ biomarkers and associations with APOE genotype in 2 longitudinal cohorts
Resnick, S. M., Bilgel, M., Moghekar, A., An, Y., Cai, Q., Wang, M., Thambisetty, M., Prince, J. L., Zhou, Y., Soldan, A., et al. (2015) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2015.04.001 · Cited by 65
Interaction between years of education and APOE ε4 status on frontal and temporal metabolism
Arenaza‐Urquijo, E. M., Gonneaud, J., Fouquet, M., Perrotin, A., Mézenge, F., Landeau, B., Egret, S., Sayette, V. D. L., Desgranges, B., & Chételat, G. (2015) · Neurology · doi:10.1212/wnl.0000000000002034 · Cited by 67
Amyloid imaging: Past, present and future perspectives
Villemagne, V. L. (2016) · Ageing Research Reviews · doi:10.1016/j.arr.2016.01.005 · Cited by 68
Influence of APOE Genotype on Hippocampal Atrophy over Time - An N=1925 Surface-Based ADNI Study
Li, B., Shi, J., Gutman, B. A., Baxter, L. C., Thompson, P. M., Caselli, R. J., Wang, Y., & Initiative, A. D. N. (2016) · PLoS ONE · doi:10.1371/journal.pone.0152901 · Cited by 67
Self-citationFan, L., Tzen, K., Chen, Y., Chen, T., Lai, Y., Yen, R., Huang, Y.-Y., Shiue, C., Yang, S., & Chiu, M. (2018) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2018.00175 · Cited by 64
Panitch, R., Hu, J., Chung, J., Zhu, C., Meng, G., Xia, W., Bennett, D. A., Lunetta, K. L., Ikezu, T., Au, R., et al. (2021) · Molecular Psychiatry · doi:10.1038/s41380-021-01266-z · Cited by 59
Apolipoprotein E Inhibits Cerebrovascular Pericyte Mobility through a RhoA Protein-mediated Pathway
Casey, C. S., Atagi, Y., Yamazaki, Y., Shinohara, M., Tachibana, M., Fu, Y., Bu, G., & Kanekiyo, T. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.625251 · Cited by 63
Differential effects of the ApoE4 genotype on brain structure and function
Matura, S., Prvulovic, D., Jurcoane, A., Hartmann, D., Miller, J., Scheibe, M., O’Dwyer, L., Oertel‐Knöchel, V., Knöchel, C., Reinke, B., et al. (2013) · NeuroImage · doi:10.1016/j.neuroimage.2013.11.042 · Cited by 63
Amyloid Imaging with PET in Early Alzheimer Disease Diagnosis
Rowe, C. C., & Villemagne, V. L. (2013) · Medical Clinics of North America · doi:10.1016/j.mcna.2012.12.017 · Cited by 62
Chiang, G. C.-Y., Mao, X., Kang, G., Chang, E., Pandya, S., Vallabhajosula, S., Isaacson, R., Ravdin, L., Initiative, A. D. N., & Shungu, D. C. (2017) · American Journal of Neuroradiology · doi:10.3174/ajnr.a5143 · Cited by 62
ApoE4 reduction: An emerging and promising therapeutic strategy for Alzheimer's disease
Li, Y., Macyczko, J. R., Liu, C.-C., & Bu, G. (2022) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2022.03.011 · Cited by 61
Gut microbiome alterations in preclinical Alzheimer’s disease
Jung, J. H., Kim, G., Byun, M. S., Lee, J. H., Yi, D., Park, H., & Lee, D. Y. (2022) · PLoS ONE · doi:10.1371/journal.pone.0278276 · Cited by 63
Edison, P., Carter, S. F., Rinne, J. O., Gelosa, G., Herholz, K., Nordberg, A. K., Brooks, D. J., & Hinz, R. (2012) · NeuroImage · doi:10.1016/j.neuroimage.2012.12.014 · Cited by 62
Byun, M. S., Park, S. W., Lee, J. H., Yi, D., Jeon, S. Y., Choi, H. J., Joung, H., Ghim, U. H., Park, U. C., Kim, Y., et al. (2021) · JAMA Ophthalmology · doi:10.1001/jamaophthalmol.2021.0320 · Cited by 60
Neuroimaging Measures as Endophenotypes in Alzheimer′s Disease
Braskie, M. N., Ringman, J. M., & Thompson, P. M. (2011) · International Journal of Alzheimer s Disease · doi:10.4061/2011/490140 · Cited by 62
Zetzsche, T., Rujescu, D., Hardy, J., & Hampel, H. J. (2010) · Expert Review of Molecular Diagnostics · doi:10.1586/erm.10.48 · Cited by 63
Lehmann, M., Ghosh, P., Madison, C. A., Karydas, A., Coppola, G., O’Neil, J. P., Huang, Y., Miller, B. L., Jagust, W., & Rabinovici, G. D. (2013) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2013-305858 · Cited by 61
Brain size and the compensation of Alzheimer's disease symptoms: A longitudinal cohort study
Guo, L., Alexopoulos, P., Wagenpfeil, S., Kurz, A., Perneczky, R., & Initiative, A. D. N. (2012) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2012.10.002 · Cited by 66
Yu, L., Lutz, M. W., Wilson, R. S., Burns, D. K., Roses, A. D., Saunders, A. M., Yang, J., Gaiteri, C., Jager, P. L. D., Barnes, L. L., et al. (2017) · PLoS ONE · doi:10.1371/journal.pone.0180356 · Cited by 61
White matter microstructure is altered in cognitively normal middle-aged APOE-ε4 homozygotes
Study, F. T. A., Operto, G., Cacciaglia, R., Grau‐Rivera, O., Falcón, C., Brugulat‐Serrat, A., Ródenas, P., Ramos, R., Morán, S., Esteller, M., et al. (2018) · Alzheimer s Research & Therapy · doi:10.1186/s13195-018-0375-x · Cited by 61
Genetics of Alzheimer’s disease: From pathogenesis to clinical usage
Shao, W., Peng, D., & Wang, X. (2017) · Journal of Clinical Neuroscience · doi:10.1016/j.jocn.2017.06.074 · Cited by 64
Shinohara, M., Sato, N., Shimamura, M., Kurinami, H., Hamasaki, T., Chatterjee, A., Rakugi, H., & Morishita, R. (2014) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2014.00071 · Cited by 60
The effects of APOE on brain activity do not simply reflect the risk of Alzheimer's disease
Trachtenberg, A. J., Filippini, N., Cheeseman, J., Duff, E. P., Neville, M. J., Ebmeier, K. P., Karpe, F., & Mackay, C. E. (2011) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2010.11.011 · Cited by 63
Working memory deficits in healthy APOE epsilon 4 carriers
Reinvang, I., Winjevoll, I. L., Rootwelt, H., & Espeseth, T. (2009) · Neuropsychologia · doi:10.1016/j.neuropsychologia.2009.10.018 · Cited by 64
Aβ Imaging: feasible, pertinent, and vital to progress in Alzheimer’s disease
Villemagne, V. L., Klunk, W. E., Mathis, C. A., Rowe, C. C., Brooks, D. J., Hyman, B. T., Ikonomović, M. D., Ishii, K., Jack, C. R., Jagust, W. J., et al. (2012) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-011-2045-0 · Cited by 58
Self-citationArold, S. P., Sullivan, P. M., Bilousova, T. V., Teng, E., Miller, C. A., Poon, W. W., Vinters, H. V., Cornwell, L. B., Saing, T., Cole, G. M., et al. (2011) · Acta Neuropathologica · doi:10.1007/s00401-011-0892-1 · Cited by 58
Goveas, J. S., Xie, C., Chen, G., Li, W., Ward, B. D., Franczak, M. B., Jones, J. L., Antuono, P., & Li, S. (2013) · PLoS ONE · doi:10.1371/journal.pone.0055902 · Cited by 59
Duara, R., Loewenstein, D., Lizarraga, G., Adjouadi, M., Barker, W., Greig‐Custo, M. T., Rosselli, M., Peñate, A., Shea, Y. F., Behar, R., et al. (2019) · NeuroImage Clinical · doi:10.1016/j.nicl.2019.101800 · Cited by 58
Self-citationAhmed, H., Wang, Y., Griffiths, W. J., Levey, A. I., Pikuleva, I. A., Liang, S. H., & Haider, A. (2024) · Brain · doi:10.1093/brain/awae028 · Cited by 61
Recent insights into the molecular genetics of dementia
Rademakers, R., & Rovelet‐Lecrux, A. (2009) · Trends in Neurosciences · doi:10.1016/j.tins.2009.05.005 · Cited by 56
Adamczuk, K., Weer, A. D., Nelissen, N., Chen, K., Sleegers, K., Bettens, K., Broeckhoven, C. V., Vandenbulcke, M., Thiyyagura, P., Dupont, P. J., et al. (2013) · NeuroImage Clinical · doi:10.1016/j.nicl.2013.04.001 · Cited by 58
Self-citationDissociation between Brain Amyloid Deposition and Metabolism in Early Mild Cognitive Impairment
Wu, L., Rowley, J., Mohades, S., Leuzy, A., Dauar, M. T., Shin, M., Fonov, V., Jia, J., Gauthier, S. G., Rosa‐Neto, P., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0047905 · Cited by 55
Swaminathan, S., Shen, L., Risacher, S. L., Yoder, K. K., West, J. D., Kim, S., Nho, K. T., Foroud, T., Inlow, M. H., Potkin, S. G., et al. (2011) · Brain Imaging and Behavior · doi:10.1007/s11682-011-9136-1 · Cited by 54
Self-citationStachel, S. J., Zerbinatti, C., Rudd, M. T., Cosden, M. L., Suon, S., Nanda, K. K., Wessner, K., DiMuzio, J. M., Maxwell, J., Wu, Z., et al. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b00176 · Cited by 59
Bilousova, T. V., Melnik, M., Miyoshi, E., Gonzalez, B. L., Poon, W. W., Vinters, H. V., Miller, C. A., Corrada, M. M., Kawas, C. H., Hatami, A., et al. (2019) · American Journal Of Pathology · doi:10.1016/j.ajpath.2019.04.010 · Cited by 57
Salvadó, G., Grothe, M. J., Groot, C., Moscoso, A., Schöll, M., Gispert, J. D., Ossenkoppele, R., & Initiative, A. D. N. (2021) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-021-05192-8 · Cited by 57
Metadata
- Authors
- Reiman, E. M., Chen, K., Liu, X., Bandy, D., Yu, M., Lee, W., Ayutyanont, N., Keppler, J., Reeder, S. A., Langbaum, J. B. S., Alexander, G. E., Klunk, W. E., Mathis, C. A., Price, J. C., Aizenstein, H. J., DeKosky, S. T., & Caselli, R. J.
- Affiliations
- Translational Genomics Research Institute (US)
- Banner - University Medical Center Phoenix (US)
- University of Arizona (US)
- Departments of iPsychiatry,
- University of Pittsburgh (US)
- Mayo Clinic in Arizona (US)
- ORCID
- Venue
- Proceedings of the National Academy of Sciences
- Publisher
- National Academy of Sciences
- Published
- 2009-04-21
- Volume
- 106
- Issue
- 16
- Pages
- 6820-6825
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- PMC
- PMC2665196
- OpenAlex
- W2171346860
- Semantic Scholar
- 50d5adab23ba1a800626a6f613f94a2c667b07e4
- Cited by
- 785
- References
- 44
- Citations by year
- 2026: 15 · 2025: 26 · 2024: 34 · 2023: 36 · 2022: 36 · 2021: 45 · 2020: 44 · 2019: 39 · 2018: 34 · 2017: 34 · 2016: 40 · 2015: 50 · 2014: 66 · 2013: 61 · 2012: 65
- FWCI
- 45.56
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Proceedings of the National Academy of Sciences (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- McKnight Foundation
- National Institute on Aging (R01AG025526, R01AG018402, P01AG025204, RF1AG025516, P50AG005133, R01AG031581, P30AG019610, R37AG025516)
- National Institute of Mental Health (R01MH070729, R01MH057899)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- fibrillar amyloid-beta, Alzheimer's disease, APOE ε4, genetic risk, cognitively normal older adults, Pittsburgh compound B PET, family history of Alzheimer's disease, mild cognitive impairment, primary prevention
- MeSH terms
- Aged, Alzheimer Disease, Brain Mapping, Cognition, Heterozygote, Homozygote, Humans, Magnetic Resonance Imaging, Middle Aged, Neuropsychological Tests, Amyloid beta-Peptides, Gene Dosage, Genetic Predisposition to Disease, Apolipoprotein E4
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
